Toshiyuki Sawa

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Yukio Ando, Hideo Saka, Maki Ando et al. · PubMed · 2000 · 788 citations

Medicine, Genetics, Pharmacology +15

Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

Shinzoh Kudoh, Koji Takeda, Kazuhiko Nakagawa et al. · Journal of Clinical Oncology · 2006 · 366 citations · Full text

Medicine, Oncology, Pharmacology +10

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yasumasa Nishimura et al. · Journal of Clinical Oncology · 2010 · 304 citations · Full text

Medicine, Oncology, Radiation Oncology +10

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

Shinji Atagi, Masaaki Kawahara, Akira Yokoyama et al. · The Lancet Oncology · 2012 · 238 citations

Medicine, Oncology, Radiation Oncology +11